Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   OpGen   /   Curetis en de Yorkville-dumpfabriek

Aandeel OpGen OTC:OPGN.Q, US68373L5057

Vertraagde koers (usd) Verschil Volume
1,960   0,000   (0,00%) Dagrange 0,000 - 0,000 0  

Curetis en de Yorkville-dumpfabriek

Volgen
25 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 10 augustus 2019 09:24
    1Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes-Share issue cap of 2.75 million shares under the first tranche of EUR 5 million in Yorkville convertible bonds has been reached-Curetis elects tosettle the excess entitlement under the first tranche in sharesElements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, USA, August1, 2019,8:00 am CEST

    –In its press release dated October 2, 2018, Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, announced thatit secured up to EUR 20 million in growth capital through the issuance of convertible notes by the Companywith share subscription warrants to YA II PN, Ltd, an investment fund managed by Yorkville Advisors Global LP, a U.S.-based management firm (the “Investor” or “Yorkville”),and that it had drawn down EUR 3.5 million of the first tranche of EUR 5 million by issuing convertible notes.

    On May 21, 2019, the Companyannounced that it had drawn down the remainder of the first tranche (i.e. EUR 1.5 million).To date, Yorkville has issued several conversion notices to convert part of the notes held by it into equity for whichthe Companyhas issued new shares. Under the terms of the agreement, the number of shares to be issued upon conversion of all convertible notes of the first tranche shall not exceed 2.75 million shares (the “First Tranche Share Issue Cap”). Any excess entitlement on the basis of the conversion ratio will be settled in cash unless the Company elects to settle such excess in shares. Yesterdayevening, the Companyreceived a further conversion noticefrom Yorkvillewhich, if fully settled in shares, would result inthe First Tranche Share Issue Cap beingexceeded. The Company will settle its obligations resulting from thisconversion notice fully in shares, thereby exercising its right under the agreement with Yorkville to settle the excess beyond the First Tranche Share Issue Capin shares. TheCompanyalso intendstoelect settlement fully in shares in respect of any furtherconversion of the remaining notes held byYorkville.The shares issued by the Company upon conversion of the first tranche of convertible notes subscribed for by Yorkville up to theFirst TrancheShare Issue Cap have been and, to the extent still available, will be issued pursuant to the authorization granted at the Company’s Annual General Meeting held on June 21, 2018 (the “2018 AGM”), which designated the Company’s management board, subject to the approval of the Company’s supervisory board, as the corporate body authorized to issue shares and/or grant rights to subscribe for shares in relation to strategic capital raising(s) and to limit or exclude pre-emption rights relating thereto.

    Any shares issued by the Company upon conversion of the first tranche of convertiblenotes subscribed for by Yorkville to settle any excess beyond the First Tranche Share Issue Capwill beissued pursuant to the 10% authorization granted at the Company’s Annual General Meetingheld on June 27, 2019(the “2019 AGM”), which designated the Company’s management board, subject to the approval of the Company’s supervisory board, as the corporate body authorized to issue shares and/or grant rights to subscribe
    2for shares in relation to general capital raising(s) and to limit or exclude pre-emption rights relating thereto. The Company may thereafter be required to seek from its shareholders further authorizations to issue additional shares upon conversion of subsequent tranches of notes and exercise of warrants prior to the funding of such subsequent tranches, based upon certain coverage requirements specified in the agreement. For the avoidance of doubt, the Company’s management board has further authorizations (i) to issue, without pre-emption rights, up to approximately 2.25 million further shares and/or rights to subscribe for shares pursuant to the authorizations granted by the 2019 AGM, but the Company may only use such authority in relation to mergers and acquisitions or strategic alliances, and (ii) to issue, with pre-emption rights, up to approximately 11.23 million further shares and/or rights to subscribe for shares pursuant to the authorizations granted by the 2019 AGM, with a view to raise additional capital to support the execution of the Company’s revised strategy and the development ofits business.

    For further details on the Yorkville convertible notes facility, please also see the “Convertibles” section under: curetis.com/investors
  2. forum rang 10 DeZwarteRidder 10 augustus 2019 09:26
    Curetis N.V.

    Hieronder vindt u informatie uit het register geplaatst kapitaal uitgevende ondernemingen. Deze informatie is door de organisatie verstrekt.

    Datum meldingsplicht 06 aug 2019
    Uitgevende instelling Curetis N.V.
    Inschrijving handelsregister 64302679
    Plaats Holzgerlingen

    Totale kapitaalverdeling
    Maand Totaal geplaatst kapitaal Totaal aantal stemmen
    246.233,97 EUR 24.623.397,00

    Vorige melding
    Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd
    Gewoon aandeel 0,01 22.917.973 1,00 0
    --------------------------------------------------------------------------
    Nieuwe melding
    Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd
    Gewoon aandeel 0,01 24.623.397 1,00 0

    Datum laatste update: 10 augustus 2019
  4. forum rang 10 DeZwarteRidder 10 augustus 2019 09:30
    Curetis N.V.

    Hieronder vindt u informatie uit het register geplaatst kapitaal uitgevende ondernemingen. Deze informatie is door de organisatie verstrekt.

    Datum meldingsplicht 19 jul 2019
    Uitgevende instelling Curetis N.V.
    Inschrijving handelsregister 64302679
    Plaats Holzgerlingen
    ----------------------------------------------------------------------
    Totale kapitaalverdeling
    Maand Totaal geplaatst kapitaal Totaal aantal stemmen
    229.179,73 EUR 22.917.973,00
    ------------------------------------------------------------------------
    Vorige melding
    Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd
    Gewoon aandeel 0,01 22.572.062 1,00 0
    -----------------------------------------------------------------------
    Nieuwe melding
    Soort aandeel Nominale waarde Aantal geplaatst Aantal stemmen per aandeel Aantal gecertificeerd
    Gewoon aandeel 0,01 22.917.973 1,00 0
  5. forum rang 10 DeZwarteRidder 10 augustus 2019 09:35
    Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville-Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing-Yorkville to provide funding of EUR 1.5 million to Curetis Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 21, 2019--Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Curetis will receive another EUR 6.5 million in gross proceeds under two financing facilities.

    Firstly, under the EIB debt financing facility originally put in place in December 2016, Curetis now stands to receive another EUR 5.0 million tranche of non-dilutive debt financing. This tranche will also have a five-year term to maturity and will require interest-only payments during that five-year term. In line with all prior tranches,the majority of interest is also deferred into the bullet repayment structure upon maturity.

    In return for EIB waiving certain conditions precedent to disbursing this EUR 5 million tranche, the parties have agreed on a 2.1% participation percentage interest (PPI). Upon maturityof the tranche, i.e. not beforearound mid-2024 (and no later than mid-2025), EIB will be entitled to an additional payment that is equity-linked and equivalent to 2.1% of the then total valuation of Curetis. All other terms and conditions of the EIB financing contract with Curetis remain unchanged.

    Secondly, under the up to EUR 20 million Yorkville convertible notes financing facilitythat was originally implemented in October 2018, Curetis has now received access to another EUR 1.5 million gross in fundingsubject to having received the aforementioned EUR 5 million tranche from EIB. Net proceeds from this tranche are expected to be about EUR 1.36million. As with the prior tranche, Yorkville is expected from time to time to convert such notes into equity and Curetis will then issue new shares. For further details on the Yorkville convertible notes facility,please also see the “Convertibles” section under: curetis.com/investors/#corporate-gove... are pleased to see continued support and funding from both EIB and Yorkville,” said Oliver Schacht, PhD, CEO of Curetis. “The additional funding will allow Curetis to continue executing on its R&D programs such as the Unyvero A30 RQplatform development towards partnering, the Unyvero LRT for BAL specimenin the US, as well as the Ares Genetics R&D programs.The Yorkville funding will also support commercial activities in the US and business development initiatives in Europeand Asia.
  6. forum rang 10 DeZwarteRidder 10 augustus 2019 10:45
    Curetis has now received access to another EUR 1.5 million gross in fundingsubject to having received the aforementioned EUR 5 million tranche from EIB. Net proceeds from this tranche are expected to be about EUR 1.36million

    Hier kunnen we precies zien wat Yorkville verdient met het dumpen van de aandelen: Yorkville krijgt een winstmarge van 140.000 op een bedrag van 1,5 miljoen; dat is dus bijna 10% winst.
  8. forum rang 7 lucas D 10 augustus 2019 11:55
    quote:

    DeZwarteRidder schreef op 10 augustus 2019 10:50:

    Hier vind je informatie over andere Yorkville-dumps:

    www.iex.nl/Forum/Topic/1267070/1/Alle...
    Lijst het in en zet het op je bureau.
    Geld lenen om een overbrugging naar een bepaald doel te realiseren kost geld, jij doet of dat abnormaal is, maar het is net zo normaal al brood bij de bakker kopen.
  9. forum rang 10 DeZwarteRidder 10 augustus 2019 12:29
    quote:

    lucas D schreef op 10 augustus 2019 11:55:

    [...]
    Lijst het in en zet het op je bureau.
    Geld lenen om een overbrugging naar een bepaald doel te realiseren kost geld, jij doet of dat abnormaal is, maar het is net zo normaal al brood bij de bakker kopen.
    Helaas voor de aandeelhouders is Curetis een bodemloze put.
  12. forum rang 10 DeZwarteRidder 10 augustus 2019 14:31
    Conversion ratio Upon a Conversion the number of newShares issuedby the Issuer to the relevantNote holder in accordance with Paragraphs 8.1 and 8.2 of this Schedule 2 will be calculated as the Conversion Amount divided by 93% of the Market Price on the applicable Conversion Date (the “Conversion Price”).The Conversion Price will be determined to two decimals places and rounded down to the nearest 100th.If the issuance of new Shares would result in the issuance of a fraction of a Share, the Issuer shall round such fraction of a Share down to the nearest whole Share.The aggregate nominal value of the Shares to be issued upon a Conversion shall be paid up by way of set-off against the aggregate Conversion Amount, with the difference being treated as unstipulated share premium.
    The Issuer shall promptly deliver freely tradable Shares to the relevant Note holder upon each Conversion of Note(s), it being specified that, in any case, the reception of the Shares, by the relevant Note holder shall occur no later than three (3) Trading Days after the Conversion Date.Upon Conversion of Notes, if the relevant Note holder does not receive the relevant Shares as provided for in the paragraph above, and if no early redemption of the Notes was requested by the relevant Note holder, at the Note holder’s discretion, the Issuer shall pay to the relevant Note holder an amount equal to the difference (if positive) between the closing price of the Share on Euronext in Amsterdam on the Conversion Date and the closing price of the Share on Euronextin Amsterdamon the day immediately prior to the date on which the relevant Shares are effectively received by the relevant Note holder, for each new Share which was issued upon the relevant Conversion of Notes.If the Issuer is unable to issue the number of Shares required upon a Conversion due tothe Issuer not having sufficient shareholders’ authorizations or sufficient authorized capital under its By-laws, and if noearly redemption of the Notes was requested by the relevant Note holder, the Issuer shall have the obligation to satisfy the number of Shares which it is unable to issue upon Conversion in cash, by paying to the Note holder, within three(3) Trading Days following the ConversionDate,an amount equal to the number of Shares it is not able to issue multiplied by the closing Share price on Euronext in Amsterdam on the Conversion Date.
  17. forum rang 10 DeZwarteRidder 11 augustus 2019 16:01
    quote:

    Fischer-R schreef op 11 augustus 2019 15:46:

    DeZwarteRidder bedankt voor de info in dit draadje, het meeste ken ik al. Wel heb ik het convertible (23 pagina's met de kleine letters) nog even doorgenomen. Voor mij persoonlijk geen beletsel om maandag mijn positie verder uit te breiden.
    Rick.
    Jammer voor je....!!

    Helaas voor de aandeelhouders wordt dit de 'opvolger' van Esperite.
  19. DAGEVOS 12 augustus 2019 09:00
    Wat staat er te gebeuren bij Curetis? Uitstel cijfers ivm overleg met Amerikaanse bank. Waarover? Extra financiering, extra deelnemers ih bedrijf, overname? Joost mag het weten. Vraag is waarom loopt de koers op? Weten sommigen meer dan wij kleine aandeelhouders? Prijsopdrijving zodat aandelen verkocht kunnen worden?
  20. forum rang 10 DeZwarteRidder 12 augustus 2019 09:23

    CuretisRetains H.C. Wainwright& Co. as Strategic Advisor-Investment bank supportsCuretis in assessment of all strategic and tactical financing options -Publication ofH1-2019 financials postponed to September18,2019-Key financials show EUR 7.8 million cash as of June30, 2019and significantly reduced cash burn in H1-2019 Elements of this announcement contain or may contain inside information within the meaning of Article 7(1) of the Market Abuse Regulation.Amsterdam, the Netherlands, and Holzgerlingen, Germany, August 12,2019, 08:00 am CET-Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has retained the U.S. based investment bank,H.C. Wainwright & Co., LLC,as strategic advisor in an effort to assess all available strategic and tactical options going forward to potentially secure appropriate funding and cash for continued operations for at least the nexttwelve months. Potential strategic options that may be explored or evaluated as part of H.C.Wainwright’smandate may include, but are not limited to,equity funding, an acquisition, merger, business combination or other strategic transaction involving Curetis.

    There is no definitive timeline for completion of the assessment process and there can beno assurance that the assessmentwouldactually result in Curetispursuing any transaction at all or that a transaction,if it were pursued,could be completed successfully. Curetisdoes not intend to discuss or disclose further developments regarding the strategic assessmentprocess unless and until its supervisory board and its management board haveapproved a specific course of action or otherwise determined that further disclosure is appropriate or required by applicable laws or regulations.

    As part of its ordinary course of business and regularinvestor relations efforts,the Company will be present at the 21stAnnual H.C. Wainwright Global Life Sciences Conferenceto be held in New York, NY, USA, on September8-10, 2019.In the context of the ongoing strategic assessment, the Company also announced that it will reschedule the publication of its 2019 First Half-Year Business and Financial Update and H1-2019 Earnings Call from its originalfinancial calendar date on August14,2019to September 18,2019.This allows for an ongoing review of H1-2019 financials by the Company’s auditors,especially in light of a series of important new IFRS standards that are now applicable,such as IFRS 16“Leases”.The Company, however, hereby reports certain preliminary, non-audited financials for the first half of 2019.

    Cash and cash equivalents as atJune30, 2019, amounted to EUR 7.8million.This includes a further EUR 5.0million tranche undera debt financing facility provided by the European Investment Bank (EIB)and the drawdown of the remainder of the first tranche (i.e. EUR 1.5 million(gross))undera convertible notesfacility provided by YA II PN, Ltd, an investment fund managed by Yorkville Advisors Global LP, both as previously announced on
    May 21, 2019.Cash burn from operations and investments in H1-2019 has been reduced by 25.7%year-over-year as a consequence of the successful implementation of certain corporate reorganization measures.The worldwide installed base of Unyvero A50 Analyzers as atJune 30, 2019, was 170, compared to162as atJune 30, 2018.This figure includes a significantly sizedpool of Analyzers now managed by Menarini Diagnostics in EMEA (9 new installations have already been identifiedfor H2-2019) as well as 37 Analyzers installed in the USA(including 20 for current and future clinical trials).
    Furthermore,as part of a campaign performed towards the end ofQ2-2019,a total of 10 refurbished Unyvero Systems were ordered by various international distribution partners with most of them being sold and shipped in H2-2019.
25 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee